Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATX NASDAQ:NTRB NASDAQ:SKIN NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.46-2.3%$3.75$1.60▼$16.31$256.95M1.2926,789 shs2.01 million shsNTRBNutriband$6.38+2.4%$7.42$3.72▼$11.78$71.16M1.13194,184 shs13,090 shsSKINBeauty Health$2.05+2.0%$1.96$0.78▼$2.56$259.99M1.231.29 million shs1.11 million shsTLSITriSalus Life Sciences$4.99-3.1%$4.69$3.42▼$5.88$248.84M0.49108,756 shs74,202 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics0.00%+2.98%-4.68%+4.22%-76.90%NTRBNutriband0.00%-1.39%-10.52%-17.14%+49.77%SKINBeauty Health0.00%-1.44%+28.93%+28.13%+4.59%TLSITriSalus Life Sciences0.00%-4.41%+35.97%-7.42%-0.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.46-2.3%$3.75$1.60▼$16.31$256.95M1.2926,789 shs2.01 million shsNTRBNutriband$6.38+2.4%$7.42$3.72▼$11.78$71.16M1.13194,184 shs13,090 shsSKINBeauty Health$2.05+2.0%$1.96$0.78▼$2.56$259.99M1.231.29 million shs1.11 million shsTLSITriSalus Life Sciences$4.99-3.1%$4.69$3.42▼$5.88$248.84M0.49108,756 shs74,202 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics0.00%+2.98%-4.68%+4.22%-76.90%NTRBNutriband0.00%-1.39%-10.52%-17.14%+49.77%SKINBeauty Health0.00%-1.44%+28.93%+28.13%+4.59%TLSITriSalus Life Sciences0.00%-4.41%+35.97%-7.42%-0.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.18Buy$12.56262.88% UpsideNTRBNutriband 3.00Buy$13.00103.76% UpsideSKINBeauty Health 2.00Hold$2.6328.05% UpsideTLSITriSalus Life Sciences 3.25Buy$10.75115.43% UpsideCurrent Analyst Ratings BreakdownLatest NTRB, SKIN, TLSI, and CATX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025SKINBeauty HealthStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$3.00 ➝ $4.007/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/ANTRBNutriband$2.14M33.24N/AN/A$0.58 per share11.00SKINBeauty Health$334.30M0.78$0.06 per share32.42$0.41 per share5.00TLSITriSalus Life Sciences$29.43M8.46N/AN/A($0.83) per share-6.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%11/11/2025 (Estimated)NTRBNutriband-$10.48M-$0.90N/AN/AN/A-415.93%-68.25%-60.40%9/9/2025 (Estimated)SKINBeauty Health-$29.10M-$0.28N/AN/AN/A-6.13%-32.82%-2.96%11/11/2025 (Estimated)TLSITriSalus Life Sciences-$30.05M-$1.18N/AN/AN/A-86.61%N/A-116.50%11/13/2025 (Estimated)Latest NTRB, SKIN, TLSI, and CATX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/9/2025N/ANTRBNutriband-$0.17N/AN/AN/A$0.71 millionN/A8/12/2025Q2 2025TLSITriSalus Life Sciences-$0.22-$0.27-$0.05-$0.27$10.69 million$11.21 million8/7/2025Q2 2025SKINBeauty Health-$0.06$0.03+$0.09$0.03$74.67 million$78.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/ANTRBNutribandN/AN/AN/AN/AN/ASKINBeauty HealthN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60NTRBNutriband0.013.713.48SKINBeauty Health4.915.154.15TLSITriSalus Life SciencesN/A4.083.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%NTRBNutriband19.70%SKINBeauty Health93.26%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.72%NTRBNutriband54.09%SKINBeauty Health41.00%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.26 million65.21 millionOptionableNTRBNutriband1011.15 million5.12 millionNot OptionableSKINBeauty Health1,030126.82 million74.83 millionOptionableTLSITriSalus Life Sciences10649.87 million36.15 millionNot OptionableNTRB, SKIN, TLSI, and CATX HeadlinesRecent News About These CompaniesRoth Capital Issues Optimistic Outlook for TLSI EarningsAugust 19, 2025 | marketbeat.comFY2025 EPS Estimates for TLSI Raised by Cantor FitzgeraldAugust 17, 2025 | marketbeat.comNorthland Capmk Has Bearish Forecast for TLSI Q3 EarningsAugust 17, 2025 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPSAugust 14, 2025 | marketbeat.comTriSalus Life Sciences Reports Strong Growth Amid ChallengesAugust 14, 2025 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comTriSalus Life Sciences Reports Strong Q2 2025 GrowthAugust 13, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comTriSalus Life Sciences backs FY25 revenue growth view up 50%August 12, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue EstimatesAugust 12, 2025 | zacks.comTriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | businesswire.comTriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference CallJuly 29, 2025 | businesswire.comTriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred StockJuly 24, 2025 | businesswire.comTriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business WireJune 25, 2025 | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital StructureJune 23, 2025 | businesswire.comTriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceMay 30, 2025 | businesswire.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTRB, SKIN, TLSI, and CATX Company DescriptionsPerspective Therapeutics NYSE:CATX$3.46 -0.08 (-2.26%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.53 +0.07 (+2.02%) As of 09/5/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Nutriband NASDAQ:NTRB$6.38 +0.15 (+2.41%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.27 -0.11 (-1.72%) As of 09/5/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Beauty Health NASDAQ:SKIN$2.05 +0.04 (+1.99%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.01 -0.04 (-1.95%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.TriSalus Life Sciences NASDAQ:TLSI$4.99 -0.16 (-3.11%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.00 +0.01 (+0.20%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
